Reimbursement news and insurance coverage updates.
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
Palmetto has expanded coverage of the ClonoSeq assay to include monitoring MRD testing for patients with chronic lymphocytic leukemia (CLL.)
The LCD for the RNA gene expression test will take effect on Feb. 10, 2020, the Medicare contractor said.
Despite the availability of more precision therapies and complex biomarker tests, systemic gaps and lack of physician education continued to hinder access.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.